Cargando…
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma
Mesothelioma is diagnosed in approximately 2,500 patients in the United States every year, most often arising in the pleural space, but also occurring as primary peritoneal mesothelioma. The vast majority of patients with mesothelioma die from their disease within 3 years. We developed a new mouse m...
Autores principales: | Guo, Yanan, Chirieac, Lucian R., Bueno, Raphael, Pass, Harvey, Wu, Wenhao, Malinowska, Izabela A., Kwiatkowski, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931745/ https://www.ncbi.nlm.nih.gov/pubmed/23851502 http://dx.doi.org/10.1038/onc.2013.280 |
Ejemplares similares
-
Heparanase inhibitors restrain mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2018) -
Association of RERG Expression with Female Survival Advantage in Malignant Pleural Mesothelioma
por: De Rienzo, Assunta, et al.
Publicado: (2021) -
Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
por: Mrozek, Evelyn M., et al.
Publicado: (2021) -
Second Generation Sequencing of the Mesothelioma Tumor Genome
por: Bueno, Raphael, et al.
Publicado: (2010) -
Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma
por: Westbom, Catherine, et al.
Publicado: (2015)